Analysts expect that Endocyte, Inc. (NASDAQ:ECYT) will post ($0.35) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Endocyte’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.51). Endocyte reported earnings per share of ($0.21) during the same quarter last year, which would suggest a negative year-over-year growth rate of 66.7%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 8th.

On average, analysts expect that Endocyte will report full-year earnings of ($1.06) per share for the current fiscal year, with EPS estimates ranging from ($1.22) to ($0.89). For the next financial year, analysts expect that the company will post earnings of ($0.85) per share, with EPS estimates ranging from ($0.89) to ($0.80). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Endocyte.

Endocyte (NASDAQ:ECYT) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.03). The company had revenue of $0.01 million during the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same period in the previous year, the company earned ($0.25) EPS.

A number of equities research analysts have weighed in on ECYT shares. Wedbush raised shares of Endocyte from a “neutral” rating to an “outperform” rating and upped their price target for the company from $2.00 to $7.00 in a report on Tuesday. ValuEngine upgraded Endocyte from a “strong sell” rating to a “sell” rating in a report on Monday. Cowen and Company reiterated a “hold” rating on shares of Endocyte in a report on Monday. Finally, Zacks Investment Research downgraded Endocyte from a “hold” rating to a “sell” rating in a report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $7.00.

Endocyte (NASDAQ ECYT) opened at 5.70 on Friday. The stock’s market cap is $242.68 million. The stock has a 50 day moving average of $1.81 and a 200-day moving average of $1.91. Endocyte has a one year low of $1.17 and a one year high of $6.55.

ILLEGAL ACTIVITY NOTICE: “Endocyte, Inc. (ECYT) Expected to Post Earnings of -$0.35 Per Share” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/10/06/endocyte-inc-ecyt-expected-to-post-earnings-of-0-35-per-share.html.

Several hedge funds and other institutional investors have recently modified their holdings of ECYT. Goldman Sachs Group Inc. raised its stake in shares of Endocyte by 1,064.3% in the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after purchasing an additional 393,975 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Endocyte by 284.4% in the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 142,461 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Endocyte in the second quarter valued at $196,000. Spark Investment Management LLC acquired a new stake in shares of Endocyte in the second quarter valued at $177,000. Finally, Parametric Portfolio Associates LLC increased its stake in shares of Endocyte by 57.8% in the first quarter. Parametric Portfolio Associates LLC now owns 162,329 shares of the biopharmaceutical company’s stock valued at $417,000 after buying an additional 59,454 shares in the last quarter. Institutional investors and hedge funds own 28.80% of the company’s stock.

Endocyte Company Profile

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.